753 results about "Capsid" patented technology

The invention discloses a lytic bacteriophage for preventing and controlling vibrio in an aquaculture environment. The bacteriophage vBValMR42H belongs to a muscle tail bacteriophage and is insensitive to chloroform, the capsid of the bacteriophage vBValMR42H is free of lipid substances, and the preservation number is GDMCC No: 67434-B1. The bacteriophage has the characteristics of high adsorption speed, short incubation period and high cracking amount, keeps high activity in a wide range of temperature (4-55 DEG C) and pH (2-11), and has strong environmental adaptability. Genome analysis shows that the bacteriophage does not contain virulence factors, antibiotic resistance genes and lyogen related genes, and is high in biological safety. Physical development analysis shows that the method can be divided into a new genus. The bacteriophage R42H has the advantages of high splitting efficiency, good environmental stability, strong specificity, gene safety and the like, and can be used as an ideal biological prevention and control agent for preventing and controlling vibrio alginolyticus diseases in aquaculture.

The present invention belongs to the technical field of biological prevention and treatment for viral diseases. Disclosed in the present invention are a tomato disease-resistant gene mutant, and the use thereof in the prevention and treatment of ToBRFV. It is found in the present invention that mutating the nucleotide at position 1927 of the coding region sequence of tomato Tm-22 gene from G to A, or mutating the amino acid at position 643 of the LRR domain of a protein that is encoded by tomato Tm-22 gene from glycine to arginine can remarkably reduce the accumulation level of ToBRFV capsid protein (CP). The gene (named Tm-22-Mut5) can serve as a novel ToBRFV resistant gene, and also retains the resistance to TMV, ToMV and ToMMV. The Tm-22-Mut5 and a pre-screened Tm-22-Mut3-1 mutant (tyrosine at position 767 of the LRR domain thereof is mutated to phenylalanine) undergo combinatorial mutagenesis to obtain a mutant Tm-22-Mut6. Analysis shows that the Tm-22-Mut6 can remarkably reduce the accumulation level of the ToBRFV capsid protein. Compared with the pFGCTm-22-Mut3-1 mutant obtained by screening in the previous research and the newly obtained mutant Tm-22-Mut5, the Tm-22-Mut6 has further improved resistance to ToBRFV.

The invention discloses a method for preparing human metapneumovirus nucleocapsid protein based on an insect-baculovirus system. Comprising the following steps: 1) constructing a recombinant vector with a human metapneumovirus nucleocapsid protein coding sequence: sequentially connecting a sequence for promoting secretory expression, the human metapneumovirus nucleocapsid protein coding sequence and a tag sequence from 5'to 3 'ends in the recombinant vector; 2) converting the recombinant vector with the human metapneumovirus nucleocapsid protein coding sequence constructed in the step 1) into a competent cell containing a baculovirus genome plasmid Bacmid to obtain a recombinant baculovirus genome plasmid; and 3) transfecting insect cells with the recombinant baculovirus genome plasmid obtained in the step 2), culturing and purifying to obtain the human metapneumovirus nucleocapsid protein. The invention provides the preparation method of the human metapneumovirus nucleocapsid protein, and a material support is provided for subsequent further research.

The invention relates to the field of aquaculture, in particular to a preparation method and application of a larimichthys crocea iridovirus recombinant live vector vaccine. According to the invention, replication-deficient type 5 adenovirus is selected as a target gene expression vector, a recombinant adenovirus vector comprising main capsid protein of iridovirus is constructed, recombinant virus is obtained, and the safe and effective large yellow croaker iridovirus disease recombinant live vector vaccine is created. According to the vaccine, the larimichthys crocea is immunized in a soaking or bait feeding mode, the CPM of the larimichthys crocea immunized by the vaccine is 12.0%, and the CPM of the fish without being immunized by the vaccine is 62.0%. In addition, the RPS of the inoculated fish and the RPS of the empty carrier control group fish are 80.65% and 9.68% respectively. The method is at a leading level in the field of pseudosciaena crocea biomedicine at present, and creativity is remarkable.

The invention discloses a panda-derived feline panleucopenia virus RAA-CRISPRCas12a detection method, and belongs to the technical field of virus detection, and the panda-derived feline panleucopenia virus RAA-CRISPRCas12a detection method comprises the following steps: S1, primer and probe design; s2, screening an RAA amplification primer; s3, RAA reaction condition optimization; s4, performing RAA sensitivity and specificity verification; s5, preparing crRNA (Complementary Ribonucleic Acid); s6, optimal crRNA screening is carried out; s7, optimizing the RAA-CRISPR / Cas12a (Reverse Amplified Architecture- S8, the specificity and the sensitivity of the RAA-CRISPR / Cas12a are verified; s9, clinical sample detection; according to the invention, by elaborately designing a primer and a probe aiming at the capsid protein VP2 gene of the feline parvovirus (FPV), fully utilizing the advantages of recombinase-mediated amplification (RAA) and a CRISPR / Cas12a system, and comprehensively optimizing reaction conditions and components of the system, the detection method has remarkable advantages, can quickly complete the detection process under the condition of constant temperature of 37 DEG C, is extremely high in sensitivity, and can be used for rapidly detecting the feline parvovirus. The lowest detection limit can reach 1 * 10 < 1 > copies / mu L, the specificity is high, and the coincidence rate with a real-time fluorescent quantitative PCR method is as high as 100%.

The disclosure relates to compositions and methods for the preparation, use, and / or formulation of adeno-associated virus capsid protein variants.

The invention relates to a new monoclonal antibody targeting the VP-1 protein of the capsid of the BK polyomavirus, fragments thereof, and uses of same for detecting infection with the BK polyomavirus. The monoclonal antibody is capable of recognizing at least all serotypes Ia, Ib2, II, III and IV of the VP-1 protein of the BK polyomavirus.

The present invention relates to methods for producing a preparation comprising recombinant AAV (rAAV), such methods comprising a step of mechanical lysis on mammalian producer cells, and methods for increasing the viral genome titre and / or capsid titre of a preparation comprising recombinant adeno-associated virus, related uses, and preparations obtained by or obtainable by the methods.

The present invention relates to treatment of COVID-19 and methods thereof. A vaccine composition for inducing immunity against coronavirus in a subject comprises a recombinant nucleic acid encoding an N-ETSD, which is a modified nucleocapsid protein comprising an endosomal targeting sequence, and / or a recombinant nucleic acid encoding an S-fusion, which is a modified spike protein with improved surface expression. The vaccines can be formulated as recombinant nucleic acids, recombinant yeasts, and / or recombinant viruses, such as adenoviruses, and can be administered via injection and / or mucosal delivery.

The present disclosure relates to pharmaceutical compositions comprising an HIV capsid inhibitor and methods for the treatment or prevention of a human immunodeficiency virus (HIV) infection in a patient.

The disclosure is directed in part to variant capsid polypeptides that can be used to deliver payloads.

The disclosure relates to compositions and methods for the preparation, use, and / or formulation of adeno-associated virus capsid protein variants.

The disclosure is directed in part to variant capsid polypeptides that can be used to deliver payloads.

The presently described and claimed disclosure relates to capillary electrophoresis methods for quantifying an intact AAV genome and protein components in an AAV using the same capillary electrophoresis system. The claimed and described approach offers an automated analysis of AAV samples and provides information to determine the AAV empty / full ratio.

The application provides a preparation method of a functionalized phage probe and application of the functionalized phage probe in detection of escherichia coli. The functionalized phage is a recombinant phage (M13KO7@SaBP) in which streptavidin binding peptide (SaBP) is fused and expressed at the N terminal of the main capsid protein P8 protein of M13K07 phage. In the application, the gene encoding SaBP (MDVEAWLGAR) is inserted into the N terminal of the P8 protein gene of M13K07 phage by site-directed mutagenesis to prepare M13K07@SaBP. The stable signal amplification is realized by using the abundant P8 protein (about 2700) of M13 phage and the super strong binding force of biotin-streptavidin, the interference of food sample matrix is reduced by combining the magnetic separation technology, and a detection method of escherichia coli with high sensitivity and small sample matrix interference is constructed.

The disclosure relates to compositions, methods, and processes for the preparation, use, and / or formulation of adeno-associated virus capsid proteins, wherein the capsid proteins comprise targeting peptide inserts for enhanced tropism to a target tissue.

Methods and compositions are provided for treating an individual in need (e.g., one who has chronic pain). Such methods can include a step of administering a therapy that reduces CamKv activity in opioid receptor mu 1 (OPRM1) expressing neurons of the individual's rostral ventromedial medulla (RVM). In some cases, the therapy (e.g., deep brain stimulation of zona incerta neurons) increases inhibitory input into the individual's RVM. In some cases, the therapy is an agent (e.g., an RNAi agent) that reduces expression or activity of CamKv in the individual's RVM. In some cases, the agent includes a retrograde-enhanced recombinant AAV particle, e.g., one that can be used to deliver an RNAi agent such as an shRNA that targets CamKv. Also provide are retrograde-enhanced clade E variant AAV capsid proteins, AVV particles that include such capsid proteins, methods of making such AAV particles, and methods of expressing a transgene using such AAVs.

The invention discloses an application of bortezomib in preparation of a medicine for resisting grouper iridovirus. Researches show that bortezomib has a remarkable inhibiting effect on grouper iridovirus, and is low in cytotoxicity and good in safety. The bortezomib can obviously reduce the fluorescence signal intensity of virus protein, inhibit the transcriptional level of main capsid protein MCP and envelope protein VP19 of the virus and reduce the copy number of DNA and mRNA of the virus; the bortezomib can effectively inhibit grouper iridovirus infection and effectively block synthesis of virus protein, so that efficient inhibition of grouper iridovirus infection is achieved, and along with prolonging of virus infection time, bortezomib can also remarkably inhibit virus gene transcription, protein synthesis and genome replication. Therefore, bortezomib not only can effectively prevent and treat grouper iridovirus infection, but also has the characteristics of high specificity, low toxicity, remarkable antiviral effect and the like, and also has important application value in prevention and control of iridovirus-related diseases in aquaculture industry.

The disclosure relates to compositions, methods, and processes for the preparation, use, and / or formulation of adeno-associated virus capsid proteins, wherein the capsid proteins comprise targeting peptide inserts for enhanced tropism to a target tissue.

According to various aspects of this disclosure, the present disclosure relates to methods for reducing kidney inflammation, reducing kidney fibrosis, reducing oxidative stress in the kidney, preventing or reducing the likelihood of chronic kidney disease (CKD), treating or preventing acute kidney injury (AKI) or treating a kidney disease in a subject in need thereof comprising administering, e.g., intramuscularly, to the subject a recombinant adeno-associated virus (rAAV) vector, wherein the rAAV vector comprises a vector genome comprising a nucleotide sequence encoding a Fibroblast growth factor 21 (FGF21) or a functional fragment thereof and an AAV capsid (e.g., AAV1 serotype), optionally, wherein the subject does not suffer from diabetes.

Recombinant myotropic AAV rh.74 capsids are described herein. In addition, plasmids, viral vectors, dual vector systems, cells, and compositions comprising or encoding such recombinant capsids are further described. Such recombinant polynucleotides, plasmids, viral vectors, dual vector systems, cells, and compositions may be used to treat muscle diseases or disorders, including muscular dystrophies and cardiomyopathies.

The present invention provides a bacteriophage having a bacteriolytic activity against Mycobacterium avium and / or Mycobacterium intracellularis, the bacteriophage having a genome containing a nucleic acid sequence represented by the genome of the bacteriophage specified by the preservation number NITE BP-03513 or NITE BP-03514 or the preservation number NITE BP-03918, the bacteriophage having a bacteriolytic activity against Mycobacterium avium and / or Mycobacterium intracellularis, and the bacteriophage having a bacteriolytic activity against Mycobacterium avium and / or Mycobacterium intracellularis. The capsid of the phage is connected with the cell-penetrating peptide through a tag.

A CVB virus expression vector comprising a PIV5 W3A viral genome comprising a mutation at amino acid residue S157 or S156 of the P / V gene and a deletion of the small hydrophobic (SH) gene of the PIV5 W3A viral genome, wherein the amino acid substitution at amino acid residue S157 or S156 comprises a substitution of serine (S) with phenylalanine (F) or asparagine (N), and the SH gene has a deletion of the SH open reading frame or the entire SH gene transcription unit. The CVB virus expression vector expresses a heterologous polypeptide, including SARS-CoV-2 spike (S), and / or nucleocapsid (N) and / or membrane (M) proteins, RSV fusion protein (F), or other antigens.

The invention discloses an antibody specifically bound with novel coronavirus nucleocapsid protein or an antigen binding fragment thereof and application thereof. The antibody or the antigen binding fragment thereof comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region comprises a CDR1 of which the amino acid sequence is shown as SEQ ID NO: 5, a CDR2 of which the amino acid sequence is shown as SEQ ID NO: 6 and a CDR3 of which the amino acid sequence is shown as SEQ ID NO: 7; the light chain variable region comprises CDR1 of which the amino acid sequence is as shown in SEQ ID NO: 8, CDR2 of which the amino acid sequence is as shown in SEQ ID NO: 9 and CDR3 of which the amino acid sequence is as shown in SEQ ID NO: 10. The antibody provided by the scheme of the invention can specifically recognize the novel coronavirus nucleocapsid protein, and has the capability of inhibiting SARS-CoV-2 N protein from inducing excessive complement activation.

Provided herein are gene therapies against PKP2 (spot phenanthrin protein-2), such as the use of adeno-associated virus (AAV) vectors. The promoter of the vector can be an MHCK7 promoter or a cardiac troponin T (cTnT2) promoter. The capsid may be AAV9 or AAVrh.74 or a capsid protein comprising AAV9 or AAVrh.74, or a functional variant thereof. Other promoters or capsids may be used. Also provided are methods of treatment, such as by intravenous, intracoronary, intracarotid, or intracardiac administration of the rAAV vector, as well as other compositions and methods.

The present invention provides novel capsid variants for viral vectors that simultaneously detarget liver tissue and efficiently transduce muscular tissue.

The present invention relates to the use of recombinant porcine adeno-associated virus (AAV) vectors comprising peptide-modified porcine AAV serotype 1 (AAVpo1) capsids in the gene therapy of muscle and / or central nervous system (CNS) disorders, particularly neuromuscular diseases such as genetic neuromuscular diseases.

A method, computer system, and apparatus for optimizing capsids for predefined characteristics are disclosed, including a computer program encoded on a computer storage medium. The system maintains candidate monomer data representing a population of one or more candidate capsid monomers. At each iteration in a series of iterations, the system updates (i) the candidate monomer data and (ii) the current values ​​of the model parameters of a first machine learning model. After performing the multiple iterations, the system selects one or more target capsid monomers from the population of candidate capsid monomers and outputs data specifying the selected target capsid monomers.